Skip to content
6-K

Foreign Interim / Material

Biodexa Pharmaceuticals Plc BDRX

0001214659-25-013673

← back to feed
Filed
Sep 12, 2025 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Diluted 2025 · Jun 30, 2025 25.27B sh
Shares Diluted 2024 · Jun 30, 2024 3.28B sh
Operating Cash Flow 2025 · Jun 30, 2025 −£3.3M
Operating Cash Flow 2024 · Jun 30, 2024 −£4.81M
Cash And Equivalents 2025 · Jun 30, 2025 £4.04M
Cash And Equivalents 2024 · Dec 31, 2024 £1.67M
Cash And Equivalents 2024 · Jun 30, 2024 £5.06M
Cash And Equivalents 2023 · Dec 31, 2023 £5.97M
Stockholders Equity 2025 · Jun 30, 2025 £11.44M
Stockholders Equity 2024 · Dec 31, 2024 £8.32M
Stockholders Equity 2024 · Jun 30, 2024 £8.73M
Stockholders Equity 2023 · Dec 31, 2023 £4.68M
Current Liabilities 2025 · Jun 30, 2025 £2.48M
Current Liabilities 2024 · Dec 31, 2024 £5.03M
Total Liabilities 2025 · Jun 30, 2025 £3.39M
Total Liabilities 2024 · Dec 31, 2024 £6.46M
Current Assets 2025 · Jun 30, 2025 £8.99M
Current Assets 2024 · Dec 31, 2024 £8.81M
Total Assets 2025 · Jun 30, 2025 £14.82M
Total Assets 2024 · Dec 31, 2024 £14.78M
Eps Diluted 2025 · Jun 30, 2025 −£0.00
Eps Diluted 2024 · Jun 30, 2024 −£0.00
Eps Basic 2025 · Jun 30, 2025 −£0.00
Eps Basic 2024 · Jun 30, 2024 −£0.00
Rd Expense 2025 · Jun 30, 2025 £1.67M
Rd Expense 2024 · Jun 30, 2024 £2.19M
Net Income 2025 · Jun 30, 2025 £3.81M
Net Income 2024 · Jun 30, 2024 £3.31M
Operating Income 2025 · Jun 30, 2025 −£4.02M
Operating Income 2024 · Jun 30, 2024 −£4.22M